Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Galderma Steps Into Biologics With Chugai Eczema Antibody

Executive Summary

Galderma has acquired most global rights to a first-in-class antibody from Chugai that will both strengthen the Swiss skin specialist's atopic dermatitis portfolio and provide its first biologic therapy.

Advertisement

Related Content

Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge
Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics
'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register